TCR² Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Initiated Phase 2 expansion portion of the ongoing gavo-cel clinical trial
- IND Clearance for Phase 1/2 clinical trial of TC-510
- 30 patients treated with gavo-cel in the expanded Phase 1 trial; dataset review in
- Updates anticipated in the second half of 2022
“We are very pleased with the momentum generated in the last quarter as we initiated the next phases on two clinical programs and expect to present in July an expanded dataset on 30 patients treated with gavo-cel,” said
- TCR² initiated the Phase 2 expansion portion of the ongoing Phase 1/2 clinical trial of gavo-cel, its first-in-class TRuC-T cell targeting mesothelin-expressing solid tumors. Enrollment is ongoing and the Company expects to report on progress from the Phase 2 portion of the clinical trial in the second half of 2022.
- TCR² announced the Company plans to present the expanded Phase 1 dataset for gavo-cel from the dose escalation portion of the Phase 1/2 clinical trial of gavo-cel in patients with treatment refractory mesothelin-expressing solid tumors in
July 2022. The presentation will focus on safety, efficacy and translational data and include 30 patients from the Phase 1 dose escalation, with data from additional malignant pleural/peritoneal mesothelioma (MPM) and ovarian patients.
- TCR² announced the
U.S. Food and Drug Administration(FDA) cleared the investigational new drug (IND) application for TC-510, a TRuC-T cell targeting mesothelin that co-expresses a PD-1:CD28 chimeric switch receptor. The Phase 1/2 clinical trial is evaluating the safety and efficacy of TC-510 in patients with mesothelin-expressing MPM, ovarian cancer, pancreatic cancer, colorectal cancer and triple negative breast cancer. The Company expects to report on progress from the Phase 1 portion of the clinical trial in the second half of 2022.
- Present the expanded Phase 1 dataset for gavo-cel in
- Provide an update from the Phase 2 portion of the ongoing gavo-cel Phase 1/2 clinical trial in the second half of 2022.
- Report initial safety, efficacy and translational data from at least one of the Phase 1 dose escalation cohorts of the TC-510 Phase 1/2 clinical trial in the second half of 2022.
- Initiate IND-enabling studies for TC-520, an enhanced CD70 targeting TRuC-T cell program, in 2022.
- Select a lead candidate for its allogeneic program in 2022.
- Production of clinical trial material to commence at ElevateBio BaseCamp as capacity is increased in anticipation of demand from the Phase 2 expansion trial of gavo-cel in 2022.
- Cash Position: TCR² ended the first quarter of 2022 with
$232.2 millionin cash, cash equivalents, and investments compared to $265.6 millionas of December 31, 2021. Net cash used in operations was $31.1 millionfor the first quarter of 2022 compared to $23.9 millionfor the first quarter of 2021. TCR² projects net cash use of $115-125 millionfor 2022, the lower end of the range previously provided. We expect cash on hand to support operations into 2024.
- R&D Expenses: Research and development expenses were
$22.9 millionfor the first quarter of 2022 compared to $15.9 millionfor the first quarter of 2021. The increase in R&D expenses was primarily due to an increase in headcount, clinical trial expenses associated with patient treatment and manufacturing, and manufacturing facilities expenses.
- G&A Expenses: General and administrative expenses were
$6.3 millionfor the first quarter of 2022 compared to $5.7 millionfor the first quarter of 2021. The increase in general and administrative expenses was due to an increase in personnel costs and other professional fees.
- Net Loss: Net loss was
$29.1 millionfor the first quarter of 2022 compared to $21.5 millionfor the first quarter of 2021.
TCR² Therapeutics management is scheduled to participate at the following upcoming conferences.
H.C. Wainwright Global Investment Conference: Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress on Tuesday, May 24, 2022at 7:00am ET
About TCR² Therapeutics
TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.
The ongoing gavo-cel Phase 1/2 clinical trial is evaluating the safety and efficacy of gavo-cel in patients with mesothelin-expressing MPM, ovarian cancer, non-small cell lung cancer (NSCLC) and cholangiocarcinoma.
In the Phase 2 portion of the clinical trial, patients will receive gavo-cel at the recommended Phase 2 dose (RP2D)(1x108 cells/m2). A total of 75 patients will be treated in the MPM cohort and a total of 20 patients will be treated in each one of the following indications: ovarian, NSCLC and cholangiocarcinoma. In the MPM cohort, patients will be randomized to receive either single agent gavo-cel, gavo-cel in combination with Opdivo (nivolumab), or gavo-cel in combination with Opdivo and Yervoy (ipilimumab). In ovarian, NSCLC and cholangiocarcinoma, all patients will receive gavo-cel in combination with Opdivo.
TC-510 is a mesothelin-targeted TRuC-T cell that co-expresses a PD-1:CD28 chimeric switch receptor to provide a local costimulatory signal by engaging with PD-L1 expressed in the hostile tumor microenvironment and converting the negative inhibitory signal into a positive costimulatory signal.
The TC-510 Phase 1/2 clinical trial is evaluating the safety and efficacy of TC-510 in patients with mesothelin-expressing MPM, ovarian cancer, pancreatic cancer, colorectal cancer and triple negative breast cancer.
The Phase 1 portion of the clinical trial utilizes a modified 3+3 design with five escalating dose levels for TC-510 (50x106, 100x106, 130x106, 160x106, and 200x106 cells). At each dose level, TC-510 will be treated with lymphodepletion chemotherapy and after the first patient is treated at each dose level, a 28-day safety observation period is instituted. Then, patients 2 and 3 may be infused simultaneously. The primary objective for the study is patient safety with a key secondary objective to determine the RP2D. In addition to standard measures of safety and efficacy, translational work includes the assessment of expansion, trafficking, and persistence of TC-510 T cells.
This press release contains forward-looking statements and information within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as "may," "will," "could", "should," "expects," "intends," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "seeks," "endeavor," "potential," "continue" or the negative of such words or other similar expressions can be used to identify forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding the therapeutic potential of gavo-cel, TC-510 and the Company’s other product candidates, expected progress and timing of updates for the gavo-cel and TC-510 clinical trials, expectations regarding clinical data for gavo-cel and TC-510 and preclinical data for our emerging pipeline and enhancements, increased manufacturing capacity and technical capabilities, including through our manufacturing partnership with
The expressed or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation: uncertainties inherent in clinical studies and in the availability and timing of data from ongoing clinical studies; whether interim results from a clinical trial will be predictive of the final results of the trial; whether results from preclinical studies or earlier clinical studies will be predictive of the results of future trials; the expected timing of submissions for regulatory approval or review by governmental authorities, including review under accelerated approval processes; orphan drug designation eligibility; regulatory approvals to conduct trials or to market products; TCR²’s ability to maintain sufficient manufacturing capabilities to support its research, development and commercialization efforts, including TCR²’s ability to secure additional manufacturing facilities; whether TCR²'s cash resources will be sufficient to fund TCR²'s foreseeable and unforeseeable operating expenses and capital expenditure requirements, the impact of the COVID-19 pandemic on TCR²’s ongoing operations; and other risks set forth under the caption "Risk Factors" in TCR²’s most recent Annual Report on Form 10-K, most recent Quarterly Report on Form 10-Q and its other filings with the
Moreover, except as required by law, neither TCR² nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Investor and Media Contact:
Senior Director, Investor Relations and Corporate Communications
UNAUDITED CONSOLIDATED BALANCE SHEETS
(amounts in thousands, except share data)
|Cash and cash equivalents||$||74,117||$||222,564|
|Prepaid expenses and other current assets||15,115||10,534|
|Total current assets||247,303||276,127|
|Property and equipment, net||18,767||17,075|
|Right-of-use assets, operating leases||55,228||28,283|
|Other assets, non-current||791||730|
|Liabilities and stockholders’ equity|
|Accrued expenses and other current liabilities||9,452||13,094|
|Operating lease liabilities||16,933||3,367|
|Total current liabilities||30,867||18,605|
|Operating lease liabilities, non-current||36,751||22,996|
|Additional paid-in capital||634,300||631,008|
|Accumulated other comprehensive income (loss)||(344||)||(13||)|
|Total stockholders’ equity||255,316||281,477|
|Total liabilities and stockholders’ equity||$||323,247||$||323,371|
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands, except share and per share data)
|Three Months Ended
|Research and development||$||22,883||$||15,924|
|General and administrative||6,320||5,668|
|Total operating expenses||29,203||21,592|
|Loss from operations||(29,203||)||(21,592||)|
|Interest income, net||117||116|
|Loss before income tax expense||(29,086||)||(21,476||)|
|Income tax expense||36||36|
|Per share information|
|Net loss per share of common stock, basic and diluted||$||(0.76||)||$||(0.58||)|
|Weighted average shares outstanding, basic and diluted||38,513,104||37,062,604|
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
|Three Months Ended
|Adjustments to reconcile net loss to cash used in operating activities:|
|Depreciation and amortization||706||513|
|Stock-based compensation expense||3,177||3,120|
|Amortization on investments||20||164|
|Deferred tax liabilities||21||36|
|Changes in operating assets and liabilities:|
|Prepaid expenses and other current assets||(4,400||)||(2,265||)|
|Operating leases, net||375||(3,808||)|
|Accrued expenses and other liabilities||(3,667||)||(1,859||)|
|Cash used in operating activities||(31,134||)||(23,927||)|
|Purchases of equipment||(1,911||)||(1,491||)|
|Software development costs||(66||)||-|
|Purchases of investments||(148,382||)||(40,732||)|
|Proceeds from sale or maturity of investments||32,989||59,287|
|Cash provided by (used in) investing activities||(117,370||)||17,064|
|Proceeds from public offering of common stock, net of issuance costs||-||131,330|
|Proceeds from the exercise of stock options||115||376|
|Payment of deferred offering costs||(56||)||(164||)|
|Cash provided by financing activities||59||131,542|
|Net change in cash, cash equivalents, and restricted cash||(148,445||)||124,679|
|Cash, cash equivalents, and restricted cash at beginning of year||223,720||94,738|
|Cash, cash equivalents, and restricted cash at end of period||$||75,275||$||219,417|
Source: TCR2 Therapeutics